Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590506 | 0.91 | KCNQ2 (0.36) | KCNQ2HPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL3599090 | 0.89 | KCNQ2 (0.37) | KCNQ2HPGDMAPTRAB9AGAA | |
| SCHEMBL3600223 | 0.86 | KCNQ2 (0.34) | KCNQ2HPGDMAPTRAB9AGAA | |
| SCHEMBL3602856 | 0.81 | KCNQ2 (0.34) | KCNQ2KMT2AMEN1L3MBTL1 | |
| SCHEMBL3601737 | 0.80 | KCNQ2 (0.38) | KCNQ2HPGDMAPTRAB9AGAA | |
| SCHEMBL4088817 | 0.79 | TP53 (0.34) | MAPTRAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3604154 | 0.77 | KCNQ2 (0.40) | KCNQ2HPGDALDH1A1KDM4EKMT2A | |
| SCHEMBL3589337 | 0.77 | KCNQ2 (0.39) | KCNQ2HPGDMAPTRAB9AGAA | |
| SCHEMBL3607325 | 0.76 | KCNQ2 (0.36) | KCNQ2HPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL3606164 | 0.75 | KCNQ2 (0.35) | KCNQ2HPGDRAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7343981-B2 | Methods using fluoroketones for: extinguishing fire; preventing fire, and reducing or eliminating the flammability of a flammable working fluid | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-03-18 | — | — | US | claimed |
| JP-2007515989-A | — | — | 2007-06-21 | — | — | JP | claimed |
| EP-1643933-A2 | METHODS USING FLUOROKETONES FOR: EXTINGUISHING FIRE; PREVENTING FIRE; AND REDUCING OR ELIMINATING THE FLAMMABILITY OF A FLAMMABLE WORKING FLUID | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050023007-A1 | Methods using fluoroketones for: extinguishing fire; preventing fire; and reducing or eliminating the flammability of a flammable working fluid | E. I. DU PONT DE NEMOURS AND COMPANY | 2005-02-03 | — | — | US | claimed |
| WO-2004112908-A2 | METHODS USING FLUOROKETONES FOR: EXTINGUISHING FIRE; PREVENTING FIRE; AND REDUCING OR ELIMINATING THE FLAMMABILITY OF A FLAMMABLE WORKING FLUID | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-12-29 | — | — | WO | claimed |
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20100222443-A1 | BLOWING AGENT COMPOSITION | ARKEMA FRANCE (FR) | 2010-09-02 | — | — | US | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-7501074-B2 | Haloketone refrigerant compositions and uses thereof | E. I. DU PONT DE NEMOURS AND COMPANY | 2009-03-10 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| WO-2004112908-A3 | METHODS USING FLUOROKETONES FOR: EXTINGUISHING FIRE; PREVENTING FIRE; AND REDUCING OR ELIMINATING THE FLAMMABILITY OF A FLAMMABLE WORKING FLUID | DU PONT (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20050033095-A1 | Fluoroketone compounds | E. I. DU PONT DE NEMOURS AND COMPANY | 2005-02-10 | — | — | US | disclosed |
| US-20050023007-A1 | Methods using fluoroketones for: extinguishing fire; preventing fire; and reducing or eliminating the flammability of a flammable working fluid | E. I. DU PONT DE NEMOURS AND COMPANY | 2005-02-03 | — | — | US | disclosed |
| US-20050023007-A1 | Methods using fluoroketones for: extinguishing fire; preventing fire; and reducing or eliminating the flammability of a flammable working fluid | E. I. DU PONT DE NEMOURS AND COMPANY | 2005-02-03 | — | — | US | disclosed |
| WO-2004112908-A2 | METHODS USING FLUOROKETONES FOR: EXTINGUISHING FIRE; PREVENTING FIRE; AND REDUCING OR ELIMINATING THE FLAMMABILITY OF A FLAMMABLE WORKING FLUID | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004112908-A2 | METHODS USING FLUOROKETONES FOR: EXTINGUISHING FIRE; PREVENTING FIRE; AND REDUCING OR ELIMINATING THE FLAMMABILITY OF A FLAMMABLE WORKING FLUID | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113260-A2 | FLUOROKETONE COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113260-A2 | FLUOROKETONE COMPOUNDS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | CNR1, CNR2, GPR18 | KCNQ2 630/4885HPGD 1416/4885MAPT 4392/4885 |
| US-20090023800-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | KCNQ2 630/4885HPGD 1416/4885MAPT 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.